Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
- PDF / 125,159 Bytes
- 1 Pages / 595.276 x 793.701 pts Page_size
- 38 Downloads / 236 Views
POSTER PRESENTATION
Open Access
Rituximab reduces the hospitalization in patients with systemic lupus erythematosus R Martínez-Pérez1*, A Fernández-Nebro2, M López-Lasanta2, M L Velloso-Feijoo1, A Muñoz-Jiménez1, J López Longo3, J L Marenco1 From 5th European Workshop on Immune-Mediated Inflammatory Diseases Sitges-Barcelona, Spain. 1-3 December 2010 Introduction Systemic Lupus Erythematosus (SLE) is a chronic inflammatory disease of unknown etiology. The evolution of the disease is unpredictable. Most patients follow a chronic course and have flare-ups or exacerbations, with a number of hospital admissions.
Table 1 Endpoints Baseline SLEDAI (0–105), median (rank)
24th week
Final Visit
14.5 (7.8-22.3) 4.0 (2.0–6.0)** 2.0 (0.0–4.0)**
PGA (0–3), median (rank)
2.8 (2.0–3.0)
0.0 (0.0–1.0)** 0.0 (0.0-1.0)
Hospitalization, n (%)
25 (54%)
1 (2.3%)**
2 (4%)**
**p
Data Loading...
